Reata is the industry leader in the development of drugs targeting Nrf2

Overview

Founded in 2002, Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. Reata is the leader in developing oral anti-inflammatory drugs targeting Nrf2, which controls the body’s production of antioxidants and has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress.

The company’s lead program, bardoxolone methyl, is an Antioxidant Inflammation Modulator (AIM) targeting Nrf2 that has been shown to significantly increase estimated glomerular filtration rate and improve several other markers of kidney function in patients with chronic kidney disease.  Bardoxolone methyl has been advanced to late-stage, pivotal clinical trials in patients with chronic kidney disease and type 2 diabetes mellitus. Chronic kidney disease is a common complication of diabetes and hypertension that affects over 26 million Americans. It is a progressive condition that ultimately leads to the need for dialysis or transplant and is also associated with a dramatic increase in the risk of cardiovascular disease, and represents an area of significant unmet medical need.

Behind this lead program, Reata is developing a portfolio of other AIMs for additional diseases of inflammation and oxidative stress. A large body of literature, including over 130 peer-reviewed articles, has demonstrated the efficacy of Reata’s AIMs in the treatment of autoimmune diseases (rheumatoid arthritis, multiple sclerosis, IB); respiratory diseases (COPD, asthma, cystic fibrosis); CNS diseases (Alzheimer’s, Parkinson’s); and transplants (graft vs. host disease), as well as the renal, cardiovascular, and metabolic diseases for which bardoxolone methyl is being developed.

Reata Approach

Several principles drive Reata’s development approach:

	Selecting superior translational research projects initiated at leading research institutions that involve novel biology with the potential to address intractable diseases.
	Advancing preclinical and clinical candidates by applying biological insights and funding prudently to advance candidates as quickly and effectively as possible.
	Selecting optimal clinical applications in which trials will be manageable in size and duration, there are well-established endpoints for pivotal studies, and there is a high regulatory imperative to approve new therapeutics.